115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C. D.; Savona, M. R.; Kishtagari, A.; Fathi, A. T.; Bhalla, K. N.; Agresta, S.; Reilly, S.; Almon, C.; Hentemann, M.; Hickman, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib maintenance therapy following revumenib-induced remission and transplant
    Meeting Abstract

    Zucenka, A.; Issa, G. C.; Arellano, M.; Khazal, S.; Khera, N.; Stock, W.; Cuglievan, B.; Gu, Y.; Nguyen, H. V.; Smith, A. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of sequential CD19-directed therapies in relapsed and refractory large B cell lymphoma
    Meeting Abstract

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M. H.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G.; Romancik, J. T.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interaction between presenting features, co-occurring mutations, MRD and induction treatment influences outcome in adults with NPM1 mutated AML - An analysis of 1357 patients in the UK NCRI AML17 and AML19 studies
    Meeting Abstract

    Othman, J.; Potter, N.; Ivey, A.; Tazi, Y.; Papaemmanuil, E.; Jovanovic, J.; Freeman, S. D.; Gilkes, A.; Thomas, I.; Johnson, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • An externally controlled trial to indirectly compare tazemetostat plus lenalidomide and rituximab versus lenalidomide and rituximab after at least one prior systemic therapy in patients with refractory and relapsed follicular lymphoma
    Meeting Abstract

    Nastoupil, L. J.; Salles, G.; Leonard, J. P.; Morschhauser, F.; Veazey, K. J.; Perrot, V.; Doban, V.; Bonnet, M.; Sosinsky, A. Z.; Crowley, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Trial in progress: Patient-reported outcome measures in the prospective observational cohort study of patients at risk for chronic graft-versus-host disease in the United States (THRIVE)
    Meeting Abstract

    Ponce, D. M.; El-Jawahri, A.; Hamilton, B. K.; Khera, N.; Bhatt, V.; Galvin, J.; Lee, C. J.
    Blood (2023)

    Fulltext@MSK | Save
  • EPCORE FL-1: Phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R (2)) Vs R (2) alone in patients with relapsed or refractory follicular lymphoma
    Meeting Abstract

    Falchi, L.; Morschhauser, F.; Linton, K.; Huang, H.; Galderisi, F.; Quadri, S.; Zeng, L.; Hoehn, D.; Seymour, J. F.
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical practice gaps in managing patients with myelofibrosis: Comparison of healthcare professional and expert treatment choices provided to an online decision support tool
    Meeting Abstract

    Topping, R. P.; Bose, P.; Mascarenhas, J.; Rampal, R. K.; Stein, B. L.; Quill, T. A.; Mesa, R. A.
    Blood (2023)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals distinct mutational signatures in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K. H.; Blaney, P.; Cirrincione, A.; Chu, T. R.; Poos, A. M.; Brown, E. E.; Manasanch, E. E.; Hoering, A.; Hou, L. M.; Gagler, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • "Defining the optimal post-CART monitoring period in recipients of axicabtagene ciloleucel and tisagenlecleucel"
    Meeting Abstract

    Wesson, W.; Lutfi, F.; Porter, D. L.; Bachanova, V.; Nastoupil, L. J.; Riedell, P. A.; Perales, M. A.; Maziarz, R. T.; Brower, J.; Shah, G. L.; more...
    Blood (2023)

    Fulltext@MSK | Save